Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists
- PMID: 19967488
- DOI: 10.1007/s10147-009-0912-5
Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists
Abstract
Background: The aim of this study was to estimate interindividual differences in the antiemetic effects of 5-HT(3) receptor antagonists by evaluating the influence of pharmacokinetics on 5-HT(3) receptor occupancies, based on receptor occupancy theory.
Methods: We analyzed interindividual differences of 5-HT(3) receptor occupancies and antiemetic effects after the oral and/or intravenous administration of standard doses of the following 5-HT(3) receptor antagonists: azasetron, granisetron, indisetron, ondansetron, ramosetron, and tropisetron.
Results: The interindividual difference between maximum and minimum 5-HT(3) receptor occupancies after oral administration ranged from 0.6% to 64.0%, and that difference after intravenous administration ranged from 0.6% to 29.6%. Following oral administration, the interindividual difference between maximum and minimum complete vomiting inhibition rates ranged from 0.2% to 16.1%. After intravenous administration, that difference ranged from 0.8% to 52.5%.
Conclusion: Interindividual differences in the clinical effects of 5-HT(3) receptor antagonists could be evaluated based on receptor occupancy theory, and the differences varied among drugs. Drug selection considering these individual variations might be useful for the patients who experienced vomiting associated with chemotherapy.
Similar articles
-
A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy.Anticancer Res. 2012 Sep;32(9):3939-47. Anticancer Res. 2012. PMID: 22993341 Clinical Trial.
-
Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):39-44. doi: 10.1007/s13318-014-0175-z. Epub 2014 Jan 28. Eur J Drug Metab Pharmacokinet. 2015. PMID: 24470169
-
[Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].Yakugaku Zasshi. 2008 Apr;128(4):649-55. doi: 10.1248/yakushi.128.649. Yakugaku Zasshi. 2008. PMID: 18379183 Japanese.
-
[Prevention and treatment of postoperative nausea and vomiting with 5-HT3-receptor blockers].Anasthesiol Intensivmed Notfallmed Schmerzther. 1996 May;31(4):200-4. doi: 10.1055/s-2007-995902. Anasthesiol Intensivmed Notfallmed Schmerzther. 1996. PMID: 8704077 Review. German.
-
[Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].Med Klin (Munich). 1998 Jan;93 Suppl 1:3-17. doi: 10.1007/BF03041988. Med Klin (Munich). 1998. PMID: 19479418 Review. German.
Cited by
-
An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.Br J Clin Pharmacol. 2017 Mar;83(3):612-622. doi: 10.1111/bcp.13145. Epub 2016 Nov 6. Br J Clin Pharmacol. 2017. PMID: 27687785 Free PMC article.
-
PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.Pharmacogenet Genomics. 2019 Jun;29(4):91-97. doi: 10.1097/FPC.0000000000000369. Pharmacogenet Genomics. 2019. PMID: 30672837 Free PMC article. No abstract available.
-
Ramosetron versus ondansetron for postoperative nausea and vomiting in strabismus surgery patients.BMC Anesthesiol. 2016 Jul 22;16(1):41. doi: 10.1186/s12871-016-0210-5. BMC Anesthesiol. 2016. PMID: 27449404 Free PMC article. Clinical Trial.
-
Theory-based analysis of clinical efficacy of triptans using receptor occupancy.J Headache Pain. 2014 Dec 8;15(1):85. doi: 10.1186/1129-2377-15-85. J Headache Pain. 2014. PMID: 25488888 Free PMC article. Clinical Trial.
-
Theoretical analysis of efficacy of biological agent for rheumatoid arthritis based on target molecular binding occupancy.Rheumatol Int. 2013 Jul;33(7):1791-5. doi: 10.1007/s00296-012-2650-7. Epub 2013 Jan 9. Rheumatol Int. 2013. PMID: 23300004
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources